is there still a glp-1 shortage The drug over. What's next for the compounders? GLP-1 No Longer on FDA's

The experiments involved 6- to 12-week-old male mice with a C57BL/6J genetic background

BaldisseraFGHolstJJKnuhtsenSHilstedLNielsenO.V

However, different side effects have been reported in treated patients, including gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, and dyspepsia

Both basic research and clinical studies have suggested that GLP-1 receptor agonists may have the potential to improve stroke recurrence and prognosis. LAMP was a multicenter, randomized controlled, prospective trial designed to evaluate the efficacy and safety of liraglutide (Victoza/Saxenda, Novo Nordisk) for the prevention of recurrent stroke after minor ischemic stroke or high-risk TIA in patients with diabetes

37 Through their anti-inflammatory and neuromodulatory actions, GLP-1 RAs may offer an additional mechanism for migraine control, particularly in cases with obesity, as it is a known risk factor for chronification

An early RCT in 44 patients with obesity and subclinical binge eating showed that liraglutide was better than diet and exercise alone in reducing binge-eating scores at 12 weeks 220 , but a later investigation of 27 adults with BED comparing liraglutide against placebo did not find any differences in the number of binging episodes over 17 weeks 218